Get notified of page updates
Enroll in Research > Research Search & Enroll Tool > Pancreatic Cancer Screening Study for High Risk People
Pancreatic Cancer Screening Study for High Risk People

Pancreatic Cancer Screening Study for High Risk People

Clinicaltrials.gov identifier:
NCT03250078

Prevention

Study Contact Information:

Contact: Tammy Lo, APRN  by phone:  203-855-3551 or by email     
Contact: Pramila Krumholtz, RN by phone: 203-739-7997 by email 
Principal Investigator: Richard Frank, MD


A Pancreatic Cancer Screening Study for High Risk Individuals

About the Study

The purpose of this study is to screen and detect pancreatic cancer and precancer in people with a strong family history of pancreatic cancer, or people with an inherited mutation and at least one first- or second-degree relative with pancreatic cancer. This includes people with (a mutation in , , , , or ) or an inherited mutation in , , CDKN2A, or .

Magnetic Resonance Imaging () will be used to screen for early pancreatic cancer. Participants will also be asked to donate a blood sample at specific intervals for the creation of a blood bank necessary for the development of a blood-based screening test for pancreatic cancer. 

What the Study Entails

  • Participants will undergo a five-minute psychological survey and donation of a blood sample every 6 months for 3 years.
  • will be performed annually for 3 years (4 in total). Cost of will be covered by the study.
  • Any abnormalities on the will be reviewed by a multi-disciplinary tumor board and discussed with the study participant.

Study Site

Norwalk, CT
Western Connecticut Health Network
Contact: Tammy Lo, APRN  by phone:  203-855-3551 or by email     
Contact: Pramila Krumholtz, RN by phone: 203-739-7997 by email    

This Study is Open To:

Men and women 50-80 years of age can participate if:

  • They have a strong family history of pancreatic cancer and 
    • at least two first-degree relatives with pancreatic cancer
    • at least three first-, second-, or third-degree relatives with pancreatic cancer with at least one pancreatic cancer in a first degree relative
  • They have (a mutation in , , , , or ) or an inherited mutation in , , CDKN2A, or and have at least one first- or second-degree relative with pancreatic cancer.
This Study is Not Open To:

People are excluded if they:

  • Have a prior history of pancreatic cancer or have cancer
  • Have a cancer that required post-treatment chemotherapy within the past 5 years
  • Received chemotherapy within the past 6 months
  • Have hereditary pancreatitis
  • Are known to have a severe reaction to a gadolinium contrast or an exam